Summit Therapeutics Share Discussion Threads

[algernon2] 02/5/2023 22:10

Hi folks, a blast from the past.

[chrisatrdg] 09/1/2023 22:18

Maybe Summit -SMMT on the NASDAQ may be worth another look see JP Morgan presentation today.

[1gw] 06/12/2022 21:44

Life in the old dog yet? No longer invested here, but noticed this headline on the Endpoints summary. Duggan seems to like SMMT as a vehicle.

"Bouncing from major setback, Summit hands out $500M cash for cancer drug — thanks to a loan from billionaire CEO"

[chrisatrdg] 04/10/2022 18:51

Thanks waterloo01 - I also saw the update & glad I bailed out last year but then added into H&W which is currently not looking good.Regards Chris

PS Hope all is well with you.

[waterloo01] 04/10/2022 14:33

Summit Therapeutics (NASDAQ:SMMT), a biotech focused on infectious diseases, dropped ~5% pre-market Tuesday after the company announced it would discontinue a pediatric clinical trial for lead asset ridinilazole for Clostridioides difficile infection.
The decision follows a Type C meeting the company conducted with the FDA in which the regulator cited the need for at least one additional registrational trial to allow a potential marketing authorization for ridinilazole.
After that, the company has decided to divest ridinilazole or seek partners to advance its studies further, SMMT said in a regulatory filing on Tuesday.
In December, the company said that its Phase 3 Ri-CoDIFy study for ridinilazole failed to meet the main goal in patients with C. difficile infection.

[clintdavid1] 19/8/2022 13:22

Up 478%-increases his stake by huge amount=arrogance?

[waterloo01] 28/7/2022 20:39

Well well the Thetons are fallible, who'd have thought it. LOL trying to raise $100m (ie 'get me outa here' Duggan.) The arrogance. Hello to all old SUMers! Glyn had a very close shave

[clarkey26] 11/1/2022 09:06

Not sure back to purely early stage, I believe they will intend to progress c-diff, ultimately the trial showed a superior SCR, just not a big enough gap to be considered statistically significant. So something which might be equally as good with SCR but with ststisticly superior reduced reoccurrence rate. They noted in the presentation this should have been a primary end point for the trial but it was designed pre their involvement.
Guess it will be down to regulatory view and cost of drug and commercialisation. Might be worth a toe back in water.
Otherwise yes seemed a lot of good talk in the presentation but nothing concrete to support it and on that front, yes very early stage!

[waterloo01] 11/1/2022 07:24

Personally I'd avoid. Back to early stage development and way too early to consider investing IMO

[chrisatrdg] 10/1/2022 21:28

Did anyone listen to todays presentation:

Summit Therapeutics Inc. (NASDAQ: SMMT) reminds interested stakeholders that it will today present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference at approximately 3:45 PM EST.

Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit’s Board of Directors, will provide details regarding Summit’s current plans with respect to its future research and clinical development goals. A live version of the presentation will be accessible on the home page of our website: hxxps://lnkd.in/dA2iEQAs. An archived edition of the session will be available later in the day.

Edit: They clearly think there is value to be obtained going forward all very enthusiastic maybe worth a punt at these low prices.

[chrisatrdg] 22/12/2021 08:23

Hi waterloo01 - I also Sold out back in September & made a modest profit.I was very wary of Duggan's decision to combine the study but from my understanding of the guy that was par for the course.

As for the future a lot depends on the 'Discuva' platform which is a big ask.

We can only wait for the publication of the C-Diff data & go from there.

Happy Christmas to all.

PS Fingers crossed for my Harland & Wolff shares.

[waterloo01] 20/12/2021 14:09

From bad to worse. Study misses end point. So combining study was sensible then. How?

Sold out sometime back as I assume we all have.

Summit Therapeutics (NASDAQ:SMMT) slumps 35.7% premarket after announcing topline results for the Phase III Ri-CoDIFy study evaluating ridinilazole, for the treatment of and Sustained Clinical Response (SCR) for patients suffering from C. difficile infection (CDI).
The study showed that ridinilazole resulted in a higher observed SCR rate than vancomycin but did not meet the study’s primary endpoint for superiority.
Patients treated with ridinilazole experienced substantially less recurrence of C. diff. infection as compared to vancomycin administered patients (nominal p-value = 0.0002).
Particularly promising results were identified in patients who were considered high-risk, including those considered immunocompromised or with a history of COVID-19 infection.
Full results from the Ri-CoDIFy study will be presented at upcoming medical conferences and published in a peer-reviewed medical journal.
C. difficile, infection is a bacterial infection of the colon that produces toxins causing inflammation of the colon, severe watery diarrhea, painful abdominal cramping, nausea, fever, and dehydration.

[chrisatrdg] 30/9/2021 12:20

Out today (No RNS):

Poster# 1052

'Characterization of the DNA binding properties of ridinilazole, a phase III antibiotic for treatment of Clostridioides difficile Infection'




Edit: Will this help ?

[chrisatrdg] 23/9/2021 11:24

Hi waterloo01 - For the first time I made the right decision with regards Summit & as I saw the share price reduce I thought thats it time to pull out.

With regards INFA soon to be HARL with the name change to Harland & Wolff Group Holdings plc from yesterday by increasing my shares my average is now 23.53 so hopefully some protection if there is a fund raise which would not be good.

There is an expected update next week on the 30th September & of course there is IM etc etc.I am looking to remain invested into next year need to achieve a doubling of the value of my my investment by then for an extension in order to future proof the house (going ground floor).

I just hope I am not going from the frying pan into the fire.

Hope you are well. Regards CM

[waterloo01] 22/9/2021 15:58

Lucky escape Chris. FDA slap down as suggested. They can't just join the two trials.

[waterloo01] 15/9/2021 11:14

Takes a while to get used to it after so long! Interesting re INFA. I keep an eye on it but seems to me they will need to raise fairly soon to pay off for the yards and while work will arrive, probably not enough as yet to meet cash flows?

Just a thought as you are 'all in'

[chrisatrdg] 15/9/2021 11:10

I have finally Sold out did so last week with a profit margin after many years invested & have risked all on INFA - fingers crossed.

PS I will still keep an eye on SUMM

[chrisatrdg] 12/8/2021 08:14

Bob Duggan is a bit of a maverick likely his idea.The trials are just taking too long to fully recruit because of COVID hence the change in approach.If data not sufficient clearly they will need to continue but does Duggan want to pour more money in. I do not believe they think they have a bad result. The markets likely to continue to put pressure on the share price it is now a bit of a gamble.Discuva is their long stop investment but early days for share price increase.

[waterloo01] 11/8/2021 22:54

Can't answer that one. But it does seem they are going for it early by combining. No idea if this approach might work. Freedosh may have a better view. Could be cut and run or a smart move. No idea.

[clarkey26] 11/8/2021 22:53

So they combine the data,unblind it and see what they have got, are they essentially saying they don't believe two studies were needed in first place and with Covid delays mean too long to wait, when believe may have sufficient data now?
Or (hoping not, given data still blind)
Do they think they know something negative and not worth burning cash on prolonging trial?
Any link to why they are expanding into new areas?
Guess just nervous after the abrupt end last time!

[chrisatrdg] 11/8/2021 21:45

Hi All - Based on the press release relating to the trials see extract below they have achieved '50% of their targeted goal' i.e. half.

This is looks like cut & run & hoping the data now supports approval see second para.

'Current enrollment in the two Ri-CoDIFy Phase III trials is 753 patients, split approximately evenly between each of the two trials. This enrollment level offers a unique opportunity to combine the studies, as the two ongoing trials have enrolled just over 50% of their targeted goal, are still blinded, and allow for a prospectively planned analysis.'

'A positive result from the combined study could form the basis of a presentation of the trial results to the regulatory authorities and inform further decisions on next steps.'

Edit: The market is thinking cut & run as I see it so once again having bought back in & now 36% up on a much lower base it is Hold or Sell again.

Edit: Each trial was for 680 participants total = 1,360 so as a % 753 for both is 55%.

[clarkey26] 11/8/2021 16:14

Hi Waterloo, that's how I read it, to me they are going to use the data they have to make a consideration against the prescribed trial measurements/end points to see if these have been achieved and if so then present to the Regulatory for consideration. Again took this to mean the Regulator could go it's positive and approve or maybe want bigger data set/trail.

So yes took it as cutting short the trial or at least if still continuing the trial then it is not stopping them seeking early approval if the data they how now if positive.

I thought this seemed positive, the market not reacted that way though!

[waterloo01] 11/8/2021 15:27

Interesting. Combining the two. Does that mean they are now recruited?